Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis

Antimicrob Agents Chemother. 2005 Dec;49(12):5139-41. doi: 10.1128/AAC.49.12.5139-5141.2005.

Abstract

Immunosuppressed mice were infected intravenously with conidia of Scedosporium prolificans. Treatment was begun 1 day later with liposomal amphotericin B, caspofungin, or both drugs initiated concurrently. Amphotericin B and caspofungin were each effective, but combined therapy did not appear to offer advantages over liposomal amphotericin B alone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Animals
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / therapeutic use*
  • Caspofungin
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Therapy, Combination
  • Echinocandins
  • Lipopeptides
  • Mice
  • Mycetoma / drug therapy*
  • Peptides, Cyclic / therapeutic use*
  • Scedosporium*

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides, Cyclic
  • liposomal amphotericin B
  • Amphotericin B
  • Caspofungin